• Year experience with exogenous lactoferrin correcting iron deficiency: first conclusions and prospects 
To content

Year experience with exogenous lactoferrin correcting iron deficiency: first conclusions and prospects 

HEALTH OF WOMAN.2015.7(103):58–62 
 

Year experience with exogenous lactoferrin correcting iron deficiency: first conclusions and prospects 
 

Melnikov S. M.

SI «Institute of urology of NAMSof Ukraine», Kyiv 
 

First experience with exogenous lactoferrin (Latoya) in gynecological practice is evidence of its effectiveness in the treatment of iron deficiency. In 80 (83.3%) patients within 30 days lactoferrin managed to significantly improve the performance of serum ferritin, hemoglobin and red blood cells. Exogenous lactoferrin has an unsurpassed safety profile: it do not cause alteration of the mucous membrane of the stomach and intestine. Practice shows that exogenous lactoferrin is able to normalize the hematologic indices for 30 days, and in severe cases 60 days, so it can be viewed as a promising alternative to the generally accepted treatment regimens iron deficiency, particularly in gynecology. 
 

Key words: exogenous lactoferrin, ferritin, hemoglobin, iron deficiency anemia, efficiency, safety. 
 

REFERENCES

1. Коваленко ВМ, Корнацький ВМ. 2008. Хвороби системи кровообігу: динаміка та аналіз. Аналітично-статистичний посібник:66–79.

2. Коноводова ЕН, Бурлев ВА. 2012. Железодефицитные состояния у беременных и родильниц. Акушерство и гинекология 1:137–142.

3. Коноводова ЕН, Бурлев ВА, Тютюнник ВЛ и др. 2011. Эффективность терапии латентного дефицита железа у беременных. Вопросы гинекологии, акушерства и перинатологии 10(5):26–30.

4. Протопопова ТА. 2012. Железодефицитная анемия и беременность. РМЖ 17:862–867.

5. Андреичев НА, Балеева ЛВ. 2009. Железодефицитные состояния и железодефицитная анемия. Вестник современной клинической медицины 3:60–65.

6. Демидова АВ. 2005. Анемии. М, МЕДпресс-информ:64.

7. Цветкова ОА. 2011. Ликферр (железо [III] – гидроксид сахарозный комплекс) – новый отечественный препарат железа для парентерального введения. РМЖ. 19;2:90–93.

8. Ayub R, Tariq N, Adil MM et al. 2008. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J. Coll. Physicians Surg. Pak. 18(7):424–7. PMid:18760066

9. Brugnara C. 2003. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin. Chem. 49(10):1573–8. http://dx.doi.org/10.1373/49.10.1573

10. Cavill I. 2002. Erythropoesis and iron. Best Practice & Research Clin. Haem. 15(2):399–409. http://dx.doi.org/10.1016/S1521-6926(02)90004-6http://dx.doi.org/10.1053/beha.2002.0004; PMid:12401314

11. Daniilidis A, Giannoulis C, Pantelis A et al. 2011. Total infusion of low molecular weight iron-dextran for treating postpartum anemia. Clin. Exp. Obstet. Gynecol. 38(2):159–61. PMid:21793279

12. Huch R, Huch A. 1995. Erythropoiesis and erythropoietin in perinatal medicine. J. Perinat. Med. 23:5–6. PMid:7658320

13. Johnson–Wimbley TD, Graham DY. 2011. Diagnosis and management of iron deficiency anemia in the 21st century. Therap. Adv. Gastroenterol. 4(3):177–84. http://dx.doi.org/10.1177/1756283X11398736; PMid:21694802 PMCid:PMC3105608

14. Khalafallah A, Dennis A, Bates J et al. 2010. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J. Intern. Med. 268(3):286–95. http://dx.doi.org/10.1111/j.1365-2796.2010.02251.x; PMid:20546462

15. Killip S, Bennett J, Chambers M. 2007, Mar 1. Iron deficiency anemia. Am Fam Physician 75(5):671–678. PMid:17375513

16. Marret H, Fauconnier A, Chabbert-Buffet N et al. 2010. Clinical practice guidelines on menorrhagia: management of abnormal uterine bleeding before menopause. Eur. J. Obstet. Gynecol. Reprod. Biol. 152(2):133–7. http://dx.doi.org/10.1016/j.ejogrb.2010.07.016; PMid:20688424

17. Parker WH, Wagner WH. 2010. Gynecologic surgery and the management of hemorrhage. Obstet. Gynecol. Clin. North. Am. 37(3):427–36. http://dx.doi.org/10.1016/j.ogc.2010.05.003; PMid:20674784

18. Perewusnyk G, Huch R, Breymann C. 2002. Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex. Br. J. Nutr. 88:3–10. http://dx.doi.org/10.1079/BJN2002577; PMid:12117422

19. Schaefer RM, Huch R, Krafft A. 2007. Anaemia Working Group. Current recommendations for the treatment of iron deficiency anemia. Rev. Med. Suisse. 105(3):874–80.

20. UNICEF/UNU/WHO. Iron Deficiency Anemia: Assessment, Prevention, and Control. A Guide for Programme Managers. Geneva: WHO/NHD, 2001.

21. Wagstrom E, Akesson A, Van Rooijen M et al. 2007. Erythropoietin and intravenous iron therapy in postpartum anaemia. Acta Obstet. Gynecol. Scand. 86(8):957–62. http://dx.doi.org/10.1080/00016340701446157; PMid:17653881

22. Paesano R, Torcia F, Berlutti F, Pacifici E, Ebano V, Moscarini M, Valenti P. 2006, Jun. Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol. 84(3):377–80. http://dx.doi.org/10.1139/o06-040; PMid:16936810

23. Nappi C, Tommaselli GA, Morra I, Massaro M, Formisano C, Di Carlo C. 2009. Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study. Acta Obstet Gynecol Scand. 88(9):1031–5. http://dx.doi.org/10.1080/00016340903117994; PMid:19639462

24. Paesano R, Berlutti F, Pietropaoli M, Goolsbee W, Pacifici E, Valenti P. 2010, Apr-Jun. Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women. Int J Immunopathol Pharmacol. 23(2):577–87. PMid:20646353